keyword
MENU ▼
Read by QxMD icon Read
search

sitagliptin cancer

keyword
https://www.readbyqxmd.com/read/28599318/sitagliptin-and-oral-cancer-risk-in-type-2-diabetes-patients
#1
Chin-Hsiao Tseng
The reimbursement database of the Taiwan's National Health Insurance was used to evaluate oral cancer risk after sitagliptin use. Patients newly diagnosed of type 2 diabetes during 1999-2008 were recruited. A 1:1 propensity score matched-pair sample of 39195 ever users and 39195 never users were followed up until December 31, 2011. Cox regression incorporated with the inverse probability of treatment weighting using propensity score was used to estimate hazard ratios. Results showed that the overall hazard ratio was not statistically significant (0...
May 27, 2017: Oncotarget
https://www.readbyqxmd.com/read/28575350/dipeptidyl-peptidase-iv-as-a-prognostic-marker-and-therapeutic-target-in-papillary-thyroid-carcinoma
#2
Jie-Jen Lee, Tao-Yeuan Wang, Chien-Liang Liu, Ming-Nan Chien, Ming-Jen Chen, Yi-Chiung Hsu, Ching-Hsiang Leung, Shih-Ping Cheng
Context: Dipeptidyl peptidase IV (DPP4) is overexpressed in thyroid cancer and certain malignancies. Furthermore, DPP4 has been identified as a discriminatory marker for thyroid cancer. However, it remains unclear whether DPP4 expression plays a prognostic role. Objective: The aim of this study was to investigate the expression and function of DPP4 in thyroid cancer and the mechanisms involved. Design: We determined the expression of DPP4 by immunohistochemistry in tissue microarrays of thyroid tumors...
May 26, 2017: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28078647/sitagliptin-a-review-in-type-2-diabetes
#3
REVIEW
Lesley J Scott
The dipeptidyl peptidase-4 inhibitor sitagliptin (Januvia(®); Glactiv(®); Tesavel(®); Xelevia™) is approved in more than 130 countries worldwide as monotherapy and in combination with other antihyperglycaemic drugs for the treatment of adult patients with type 2 diabetes (T2D). Extensive clinical experience has firmly established the glycaemic efficacy of oral sitagliptin (±other antihyperglycaemic drugs) in a broad spectrum of patients with T2D, including obese, elderly and renally impaired patients and those with established cardiovascular (CV) disease (CVD)...
February 2017: Drugs
https://www.readbyqxmd.com/read/28057693/assessing-the-safety-of-sitagliptin-in-older-participants-in-the-trial-evaluating-cardiovascular-outcomes-with-sitagliptin-tecos
#4
M Angelyn Bethel, Samuel S Engel, Jennifer B Green, Zhen Huang, Robert G Josse, Keith D Kaufman, Eberhard Standl, Shailaja Suryawanshi, Frans Van de Werf, Darren K McGuire, Eric D Peterson, Rury R Holman
OBJECTIVE: Limited data exist regarding safety and efficacy of antihyperglycemic drugs in older patients with type 2 diabetes. The Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) was a randomized, double-blind, placebo-controlled trial assessing the impact of sitagliptin on a primary composite outcome of cardiovascular death, nonfatal stroke, nonfatal myocardial infarction, or unstable angina hospitalizations in patients with type 2 diabetes (HbA1c ≥6.5% [48 mmol/mol] and ≤8...
April 2017: Diabetes Care
https://www.readbyqxmd.com/read/27986440/sitagliptin-may-reduce-breast-cancer-risk-in-women-with-type-2-diabetes
#5
Chin-Hsiao Tseng
BACKGROUND: Whether sitagliptin may affect breast cancer risk remains to be answered. This study evaluated such an association in Taiwanese female patients with type 2 diabetes. METHODS: A retrospective cohort of female patients with newly diagnosed type 2 diabetes at an age ≥ 25 years between 1999 and 2010 was recruited from the National Health Insurance database. A total of 32,457 ever-users and 396,021 never-users of sitagliptin were followed until December 31, 2011...
June 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/27745828/efficacy-and-safety-of-dpp-4-inhibitors-in-patients-with-type-2-diabetes-meta-analysis-of-placebo-controlled-randomized-clinical-trials
#6
MULTICENTER STUDY
M B Rehman, B V Tudrej, J Soustre, M Buisson, P Archambault, D Pouchain, H Vaillant-Roussel, F Gueyffier, J-L Faillie, M-C Perault-Pochat, C Cornu, R Boussageon
BACKGROUND: Guidelines for type 2 diabetes (T2D) recommend reducing HbA1c through lifestyle interventions and glucose-lowering drugs (metformin, then combination with dipeptidyl peptidase-4 inhibitors [DPP-4Is] among other glucose-lowering drugs). However, no double-blind randomized clinical trial (RCT) compared with placebo has so far demonstrated that DDP-4Is reduce micro- and macrovascular complications in T2D. Moreover, the safety of DPP-4Is (with increased heart failure and acute pancreatitis) remains controversial...
February 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/27661113/sitagliptin-may-reduce-prostate-cancer-risk-in-male-patients-with-type-2-diabetes
#7
Chin-Hsiao Tseng
This retrospective cohort study evaluated the risk of prostate cancer associated with sitagliptin use in Taiwanese male patients with type 2 diabetes mellitus by using the reimbursement databases of the National Health Insurance. Male patients with newly diagnosed type 2 diabetes mellitus at an age ≥25 years between 1999 and 2010 were recruited. A total of 37,924 ever users of sitagliptin and 426,276 never users were followed until December 31, 2011. The treatment effect of sitagliptin (for ever versus never users, and for tertiles of cumulative duration of therapy) was estimated by Cox regression incorporated with the inverse probability of treatment weighting using propensity score...
March 21, 2017: Oncotarget
https://www.readbyqxmd.com/read/27630212/pancreatic-safety-of-sitagliptin-in-the-tecos-study
#8
John B Buse, M Angelyn Bethel, Jennifer B Green, Susanna R Stevens, Yuliya Lokhnygina, Pablo Aschner, Carlos Raffo Grado, Tsvetalina Tankova, Julio Wainstein, Robert Josse, John M Lachin, Samuel S Engel, Keyur Patel, Eric D Peterson, Rury R Holman
OBJECTIVE: We evaluated the incidence of acute pancreatitis and pancreatic cancer in patients with type 2 diabetes and cardiovascular disease who were treated with sitagliptin, a dipeptidyl peptidase-4 inhibitor (DPP-4i). RESEARCH DESIGN AND METHODS: In the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) study, a cardiovascular safety study of sitagliptin, all suspected cases of acute pancreatitis and pancreatic cancer were collected prospectively for 14,671 participants during a median follow-up time of 3 years, and were adjudicated blindly...
February 2017: Diabetes Care
https://www.readbyqxmd.com/read/27075625/nrf2-activation-by-antioxidant-antidiabetic-agents-accelerates-tumor-metastasis
#9
Hui Wang, Xiufei Liu, Min Long, Yi Huang, Linlin Zhang, Rui Zhang, Yi Zheng, Xiaoyu Liao, Yuren Wang, Qian Liao, Wenjie Li, Zili Tang, Qiang Tong, Xiaocui Wang, Fang Fang, Montserrat Rojo de la Vega, Qin Ouyang, Donna D Zhang, Shicang Yu, Hongting Zheng
Cancer is a common comorbidity of diabetic patients; however, little is known about the effects that antidiabetic drugs have on tumors. We discovered that common classes of drugs used in type 2 diabetes mellitus, the hypoglycemic dipeptidyl peptidase-4 inhibitors (DPP-4i) saxagliptin and sitagliptin, as well as the antineuropathic α-lipoic acid (ALA), do not increase tumor incidence but increase the risk of metastasis of existing tumors. Specifically, these drugs induce prolonged activation of the nuclear factor E2-related factor 2 (NRF2)-mediated antioxidant response through inhibition of KEAP1-C151-dependent ubiquitination and subsequent degradation of NRF2, resulting in up-regulated expression of metastasis-associated proteins, increased cancer cell migration, and promotion of metastasis in xenograft mouse models...
April 13, 2016: Science Translational Medicine
https://www.readbyqxmd.com/read/27039825/effects-of-epothilone-a-in-combination-with-the-antidiabetic-drugs-metformin-and-sitagliptin-in-hepg2-human-hepatocellular-cancer-cells-role-of-transcriptional-factors-nf-%C3%AE%C2%BAb-and-p53
#10
Aneta Rogalska, Agnieszka Sliwinska, Jacek Kasznicki, Jozef Drzewoski, Agnieszka Marczak
Type 2 diabetes mellitus patients are at increased risk of many forms of malignancies, especially of the pancreas, colon and hepatocellular cancer. Unfortunately, little is known of the possible interaction between antidiabetic drugs and anticancer agents. The present study investigates the influence of metformin (MET) and sitagliptin (SITA) on the in vitro anticancer activity of the microtubule depolymerization inhibitor agent epothilone A (EpoA). Hepatocellular liver carcinoma cell line (HepG2) viability and apoptosis were determined by the MTT test and by double staining with PO-PRO-1 and 7-aminoactinomycin D, respectively, after treatment with EpoA, metformin or sitagliptin...
2016: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/27029076/sitagliptin-use-and-thyroid-cancer-risk-in-patients-with-type-2-diabetes
#11
Chin-Hsiao Tseng
Whether sitagliptin may increase thyroid cancer risk has not been investigated in the Asian populations. This study evaluated the association in Taiwanese patients with newly diagnosed type 2 diabetes from 1999 to 2008 by using the reimbursement database of the National Health Insurance. They should have been followed for at least 6 months after March 1, 2009, the date when sitagliptin was approved for reimbursement. Patients newly treated with sitagliptin (n=58238, "ever users of sitagliptin") or other antidiabetic drugs (n =312853, "never users of sitagliptin") were followed until December 31, 2011...
April 26, 2016: Oncotarget
https://www.readbyqxmd.com/read/26880912/effect-of-metformin-and-sitagliptin-on-doxorubicin-induced-cardiotoxicity-in-rats-impact-of-oxidative-stress-inflammation-and-apoptosis
#12
Mina Thabet Kelleni, Entesar Farghaly Amin, Aly Mohamed Abdelrahman
Doxorubicin (DOX) is a widely used antineoplastic drug whose efficacy is limited by its cardiotoxicity. The aim of this study was to investigate the possible protective role of the antidiabetic drugs metformin (250 mg/kg dissolved in DW p.o. for seven days) and sitagliptin (10 mg/kg dissolved in DW p.o. for seven days) in a model of DOX-induced (single dose 15 mg/kg i.p. at the fifth day) cardiotoxicity in rats. Results of our study revealed that pretreatment with metformin or sitagliptin produced significant (P < 0...
2015: Journal of Toxicology
https://www.readbyqxmd.com/read/26816911/evaluation-of-anti-cancer-effects-of-dpp-4-inhibitors-in-colon-cancer-an-invitro-study
#13
C A Amritha, Punnagai Kumaravelu, D Darling Chellathai
INTRODUCTION: Among the oral anti-diabetic drugs, Dipeptidyl peptidase - 4(DPP-4) inhibitor is an emerging class of drugs. Inhibitors of DPP-4 enzyme like Sitagliptin and Vildagliptin have shown Anti-oxidant properties in many studies, both invivo and invitro. It has also been characterized as an apoptotic agent on pancreatic cancer cells. In the following study, Anticancer effect of DPP 4 inhibitors on colon cell lines (HT-29) using MTT assay- {3 -4, 5-dimethyl (thiazol - 2 -yl) -3, 5- dimethyl tetrazolium bromide} assay was elucidated...
December 2015: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/26584246/sitagliptin-and-pancreatic-cancer-risk-in-patients-with-type-2-diabetes
#14
Chin-Hsiao Tseng
BACKGROUND: The risk of pancreatic cancer associated with incretin-based therapies is controversial. METHODS: This study retrospectively analysed the National Health Insurance database including patients with newly diagnosed type 2 diabetes mellitus at an age ≥ 25 years between 1999 and 2010. A total of 71 137 ever users of sitagliptin and 933 046 never users were followed for pancreatic cancer until 31 December 2011. A time-dependent approach was used to calculate incidence and estimate hazard ratios adjusted for propensity score using Cox regression...
January 2016: European Journal of Clinical Investigation
https://www.readbyqxmd.com/read/26267432/dipeptidyl-peptidase-4-promotes-epithelial-cell-transformation-and-breast-tumourigenesis-via-induction-of-pin1-gene-expression
#15
H J Choi, J Y Kim, S-C Lim, G Kim, H J Yun, H S Choi
BACKGROUND AND PURPOSE: Dipeptidyl peptidase 4 (DPP4) is an aminopeptidase that is widely expressed in different cell types. Recent studies suggested that DPP4 plays an important role in tumour progression in several human malignancies. Here we have examined the mechanisms by which up-regulation of DPP4 expression causes epithelial transformation and mammary tumourigenesis. EXPERIMENTAL APPROACH: Expression of DPP4 and the peptidylprolyl cis/trans isomerase, NIMA-interacting 1 (PIN1), and the cytotoxic effects of combined treatment with sitagliptin and juglone were investigated by immunohistochemistry, immunoblotting, real-time PCR, TUNEL and soft agar assays, using MCF7 cells...
November 2015: British Journal of Pharmacology
https://www.readbyqxmd.com/read/26222679/differential-expression-and-enzymatic-activity-of-dppiv-cd26-affects-migration-ability-of-cervical-carcinoma-cells
#16
Aline Beckenkamp, Júlia Biz Willig, Danielle Bertodo Santana, Jéssica Nascimento, Juliano Domiraci Paccez, Luiz Fernando Zerbini, Alessandra Nejar Bruno, Diogo André Pilger, Márcia Rosângela Wink, Andréia Buffon
Dipeptidyl peptidase IV (DPPIV/CD26) is a transmembrane glycoprotein that inactivates or degrades some bioactive peptides and chemokines. For this reason, it regulates cell proliferation, migration and adhesion, showing its role in cancer processes. This enzyme is found mainly anchored onto the cell membrane, although it also has a soluble form, an enzymatically active isoform. In the present study, we investigated DPPIV/CD26 activity and expression in cervical cancer cell lines (SiHa, HeLa and C33A) and non-tumorigenic HaCaT cells...
2015: PloS One
https://www.readbyqxmd.com/read/26052984/effect-of-sitagliptin-on-cardiovascular-outcomes-in-type-2-diabetes
#17
RANDOMIZED CONTROLLED TRIAL
Jennifer B Green, M Angelyn Bethel, Paul W Armstrong, John B Buse, Samuel S Engel, Jyotsna Garg, Robert Josse, Keith D Kaufman, Joerg Koglin, Scott Korn, John M Lachin, Darren K McGuire, Michael J Pencina, Eberhard Standl, Peter P Stein, Shailaja Suryawanshi, Frans Van de Werf, Eric D Peterson, Rury R Holman
BACKGROUND: Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease. METHODS: In this randomized, double-blind study, we assigned 14,671 patients to add either sitagliptin or placebo to their existing therapy. Open-label use of antihyperglycemic therapy was encouraged as required, aimed at reaching individually appropriate glycemic targets in all patients...
July 16, 2015: New England Journal of Medicine
https://www.readbyqxmd.com/read/25959860/metformin-but-not-sitagliptin-enhances-wp-631-induced-apoptotic-hepg2-cell-death
#18
Agnieszka Sliwinska, Aneta Rogalska, Agnieszka Marczak, Jacek Kasznicki, Jozef Drzewoski
Metformin and sitagliptin are hypoglycemic drugs with potential use in cancer treatment. Evidence indicates that metformin may inhibit the proliferation and growth of various types of cancer cells. Data regarding the relationship between sitagliptin and cancer cells is limited. Therapy based on anthracycline derivatives, mainly doxorubicin, is commonly used in the treatment of resistant liver cancers. WP 631 is a new structural analogue of doxorubicin that exerts an anticancer action by the induction of apoptosis...
August 2015: Toxicology in Vitro: An International Journal Published in Association with BIBRA
https://www.readbyqxmd.com/read/25694411/dapagliflozin-a-new-sodium-glucose-cotransporter-2-inhibitor-for-treatment-of-type-2-diabetes
#19
REVIEW
Eva M Vivian
PURPOSE: The pharmacologic properties and clinical efficacy of dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes, are reviewed. SUMMARY: Dapagliflozin (Farxiga, AstraZeneca) is a selective SGLT2 inhibitor approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Dapagliflozin lowers blood glucose independent of insulin secretion and action by inhibiting renal reabsorption of glucose, thus promoting increased urinary excretion of glucose...
March 1, 2015: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/25630605/safety-of-dipeptidyl-peptidase-4-inhibitors-for-treating-type-2-diabetes
#20
REVIEW
André J Scheen
INTRODUCTION: Dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) occupy a growing place in the armamentarium of drugs used for the management of hyperglycemia in type 2 diabetes, although some safety concerns have been raised in recent years. AREAS COVERED: An updated review providing an analysis of available safety data (meta-analyses, randomized controlled trials, observational cohort and case-control studies and pharmacovigilance reports) with five commercialized DPP-4 inhibitors (sitagliptin, vildagliptin, saxagliptin, alogliptin, linagliptin)...
April 2015: Expert Opinion on Drug Safety
keyword
keyword
118468
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"